NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 362 filers reported holding NOVOCURE LTD in Q2 2021. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $310,000 | +54.2% | 1,397 | -8.1% | 0.01% | +80.0% |
| Q1 2021 | $201,000 | +200.0% | 1,520 | +153.3% | 0.01% | +66.7% |
| Q3 2020 | $67,000 | -38.5% | 600 | -67.3% | 0.00% | -50.0% |
| Q2 2020 | $109,000 | -90.3% | 1,836 | -92.2% | 0.01% | -90.5% |
| Q1 2019 | $1,127,000 | +33.5% | 23,403 | -7.2% | 0.06% | +10.5% |
| Q4 2018 | $844,000 | -38.9% | 25,215 | -4.4% | 0.06% | -28.8% |
| Q3 2018 | $1,382,000 | +65.7% | 26,369 | -1.0% | 0.08% | +50.9% |
| Q2 2018 | $834,000 | +56.2% | 26,634 | +8.7% | 0.05% | +35.9% |
| Q1 2018 | $534,000 | -0.7% | 24,513 | -8.0% | 0.04% | -9.3% |
| Q4 2017 | $538,000 | +186.2% | 26,634 | +181.5% | 0.04% | +152.9% |
| Q3 2017 | $188,000 | -44.2% | 9,461 | -76.0% | 0.02% | -51.4% |
| Q3 2016 | $337,000 | – | 39,483 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |